SUMMARY The isoelectric point (pI) ofthe major form of Bence-Jones protein excreted by 62 patients with myeloma and six with macroglobulinaemia was measured by combining isoelectric focusing with immunoblotting techniques. The distribution of the pI values for both K and A type proteins was bimodal, most falling in the ranges 5-0-6 0 and 7s07-5. Plasma creatinine and creatinine clearance and the urine excretion of ac-1-microglobulin and ,B-2-microglobulin were measured in 24 of the patients. These patients, who were free of additional factors known to have an association with the development ofrenal impairment, were followed up for a mean period of 16 months (range three to 28 months). It was found that renal impairment was not related to the pI of the Bence-Jones protein excreted.
Although the occurrence of Bence-Jones proteinuria in patients with myeloma is strongly associated with renal failure,' the development of renal impairment is not predictable, and in some cases Bence-Jones protein may continue to be excreted with minimal renal malfunction.' Other features ofthe disease such as hypercalcaemia, or the use of nephrotoxic drugs, may be responsible for this complication.
It has been proposed that the physical properties of the Bence-Jones protein are important in determining whether renal impairment develops.'4 Thus it has been claimed that Bence-Jones proteins of relatively high isoelectric point (pl) are more likely to be associated with renal impairment than those of low pI and it has been suggested that this might be due to a strong ionic interaction with the acidic Tamm-Horsfall glycoprotein (pl [3] [4] [5] or other tubular proteins at the pH occurring within the renal tubule.'4 Such interactions might lead to cast formation or tubulopathy and eventually glomerular failure. The combined evidence from animal models' and clinical studies,79 however, is contradictory.
We recently developed a method, combining isoelectric focusing and immunoblotting, which permits the direct measurement of the pl of BenceJones proteins.'0 This new procedure has the major advantage that preliminary concentration, electrophoresis, or liquid chromatography of the urine speciman is unnecessary."8 Using this technique we investigated the association between the pl values of Accepted for publication 11 July 1988 Bence-Jones proteins and several indices of both glomerular and tubular function.
Patients and methods
Sixty two patients with myeloma and six with macroglobulinaemia were studied. All were excreting Bence-Jones protein and all those with myeloma fulfilled the diagnostic criteria used in the first United Kingdom myelomatosis trial organised by the Medical Research Council." Twenty four patients were studied sequentially in more detail; these were selected by exclusion of those with some additional complicating factor that could predispose to the development of renal impairment, and by eliminating those who had a history of renal disease before developing myeloma. The former exclusions included patients with hypercalcaemia, hyperuricaemia, or hypercalciuria, either before or after rehydration. Those who had begun chemotherapy were also excluded, apart from six who had received a dose well below that reported as causing renal impairment: these six patients had received only one or two of the usual nine courses of a standard regimen which comprised melphalan (025 mg/kg/day) and prednisolone (1 mg/kg/day) for four days every six weeks.
The pl of the major Bence-Jones protein excreted, the plasma creatinine and creatinine clearance, and the urinary excretion of a-1 -microglobulin and P-2- Norden, Flynn, Fulcher, Richards measurement of the pl values of the Bence-Jones proteins were performed as described previously.'0'2 Bence-Jones protein excretion was estimated semiquantitatively by applying a volume of urine containing 25 nmol creatinine to the isoelectric focusing gels and using a previously described scoring system.'"12
Two dimensional isoelectric focusing and electrophoresis was carried out using pl 3-10 ampholytes according to Pharmacia Application Note No 52-1464 00-04 (Pharmacia Ltd, Central Milton Keynes, Buckinghamshire). Such gels were immunoblotted as described previously.'0 Alpha-l-microglobulin was measured by solidphase enzyme immunoassay using "Imzyme alpha-1-m" reagents (Diamed Diagnostics Ltd, Bootle, Merseyside). Beta-2-microglobulin was quantitated by the "Beta-2-micro" kit (Pharmacia). Creatinine was determined in plasma by an end point alkaline picrate method using a "SMAC" Analyzer (Technicon Ltd, Basingstoke, Hampshire), and in urine by a rate reaction alkaline picrate method using an "Astra" analyser (Beckman Ltd, High Wycombe, Buckinghamshire).
Results
The frequency distribution of the measured pl values of the major form of Bence-Jones protein excreted by the 68 patients with myeloma or macroglobulinaemia When the rate of change in the reciprocal of the plasma creatinine and in the excretion of a-1-and f-2-microglobulins was examined in relation to the pl values of the Bence-Jones proteins, no significant correlations were detected.
* :
When we measured the electrophoretic mobility of eight Bence-Jones proteins over a pH gradient, using isoelectric focusing and electrophoresis performed at right angles to one another (fig 4) , we found a good correlation between the electrophoretic mobility ofthe proteins at pH 6 and the pl of the protein ( fig 5) . Discussion is, with pl values There have been two previous studies of the associatcommon.
tion between the pI of Bence-Jones proteins and the ne and creatinine development of renal impairment in patients with e of presentation myeloma. Coward et al found that the occurrence of ional recognised Bence-Jones protein with a high pI had a definite n plotted against correlation with reduced creatinine clearance.7 More ing Bence-Jones recently, Johns et al reported that proximal tubular on between the function, as measured by the urinary a-1-of Bence-Jones microglobulin content, was more severely impaired in patients excreting Bence-Jones protein of high pl globulin excreted value, but that there was no association with the serum ional recognised creatinine concentration. 8 We have not confirmed n plotted against either of the positive associations reported in these studies. It may be important that both these groups of authors used less direct approaches to pI measurement than ourselves; nevertheless, it is unlikely that electrophoresis after preliminary concentration of the urine7 or fast protein liquid chromatography8 would bias the pI measurements in relation to the presence or absence of renal impairment. It is more likely that different criteria used for the selection of patients, unsuspected heterogeneity in the aetiology of renal impairment, or chance bias in population sampling contributed to the different findings.
In the context ofthe possible nephrotoxicity ofsome Bence-Jones proteins three criticisms of the relevance of in vitro pI measurements are apparent. First, the pl * is not the critical variable in a charge-related hypothesis of nephrotoxicity; it is net charge at the pH --, prevailing at the site of toxicity that should matter.
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Norden, Flynn, Fulcher, Richards prevailing in the kidney is unknown. Thirdly, it is uncertain whether charge interactions between BenceJones proteins and renal tissue or urine constituents will be clinically important at the pH values and ionic strengths prevailing within the renal tubule.
We measured electrophoretic mobility at pH 6 to provide an indication of the charge carried by BenceJones proteins. The good correlation we found between this mobility and the pl of the proteins suggests that the pl provides a good measure of net charge at a physiological pH and that pI measurements are relevant to the testing of a chargebased hypothesis ofthe nephrotoxicity of Bence-Jones proteins. In this context it is of interest that Hill et al found that there was an excellent correlation between decreasing electrophoretic mobility of the light chain protein excreted and increasing serum urea concentration among 17 patients with myeloma and BenceJones proteinuria.9 This association was attributed to the effects of the charge of the molecule on either its polymerisation or the quantity that could be filtered at the glomerulus. Unfortunately, the pH at which they measured the electrophoretic mobility of the light chains was not specified.
A fundamental difficulty complicating the interpretation of all the studies that have attempted to relate the charge on Bence-Jones proteins to nephrotoxicity is that the quantity of Bence-Jones protein reaching the renal tubule is unknown. As has been pointed out by Rosansky et al it is not valid to assume that the amount excreted can be directly related to the quantity entering the glomerular filtrate. '3 Interest in the pl of Bence-Jones proteins was stimulated by in vitro studies ofnephrotoxicity. 4 Other investigations, such as those of light chain polymerisation,'4 have failed to show physical properties which might affect nephrotoxicity. If physical characterisation of Bence-Jones proteins permitted the identification of a subgroup of patients at particular risk ofdeveloping renal impairment, such patients could be given intensive prophylaxis. A study such as this cannot prove that the net charge on a Bence-Jones protein is unimportant in the processes which underlie renal impairment, but our findings do suggest that the pl of the protein is a poor clinical guide.
